SAR 408701

Drug Profile

SAR 408701

Alternative Names: SAR408701

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunoGen
  • Developer Sanofi
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 30 May 2017 ImmunoGen and Sanofi amends a licensing agreement granting exclusive, fully-paid license of SAR 408701 to Sanofi
  • 29 Nov 2016 Adverse events, efficacy and pharmacokinetics data from a phase I trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • 07 Oct 2016 SAR 408701 is still in phase I trials for Solid tumours (Late-stage disease, Metastatic disease) in Canada (NCT02187848)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top